CoChat

Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification

Open access
Kleeman, Sam O, Koelzer, Viktor H, Jones, Helen JS, Vazquez, Ester Gil, Davis, Hayley, East, James E, Arnold, Roland, Koppens, Martijn AJ, Blake, Andrew, Domingo, Enric, Cunningham, Chris, Beggs, Andrew D, Pestinger, Valerie, Loughrey, Maurice B, Wang, Lai-Mun, Lannagan, Tamsin RM, Woods, Susan L, Worthley, Daniel, Tomlinson, Ian, Dunne, Philip D, Maughan, Timothy, Leedham, Simon J · 2020 · Gut
Cited by 73

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objective: Pathological Wnt pathway activation is a conserved hallmark of colorectal cancer. Wnt-activating mutations can be divided into: i) ligand-independent (LI) alterations in intracellular signal transduction proteins (Adenomatous polyposis coli, β-catenin), causing constitutive pathway activation and ii) ligand-dependent (LD) mutations affecting the synergistic R-Spondin axis (RNF43,RSPO-fusions) acting through amplification of endogenous Wnt signal transmembrane transduction. Our aim was to exploit differential Wnt target gene expression to generate a mutation-agnostic biomarker for LD tumours. Design: We undertook harmonised multi-omic analysis of discovery (n=684) and validation cohorts (n=578) of colorectal tumours collated from publicly available data and the Stratification in Colorectal Cancer Consortium. We used mutation data to establish molecular ground truth and subdivide lesions into LI/LD tumour subsets. We contrasted transcriptional, methylation, morphological and clinical characteristics between groups. Results: Wnt disrupting mutations were mutually exclusive. Desmoplastic stromal upregulation of RSPO may compensate for absence of epithelial mutation in a subset of stromal-rich tumours. Key Wnt negative regulator genes were differentially expressed between LD/LI tumours, with targeted hypermethylation of some genes (AXIN2,NKD1) occurring even in CIMP-negative LD cancers.AXIN2 mRNA expression was used as a discriminatory molecular biomarker to distinguish LD/LI tumours (area under the curve >0.93). Conclusions: Epigenetic suppression of appropriate Wnt negative feedback loops is selectively advantageous in LD tumours and differential AXIN2 expression in LD/LI lesions can be exploited as a molecular biomarker. Distinguishing between LD/LI tumour types is important; patients with LD tumours retain sensitivity to Wnt ligand inhibition and may be stratified at diagnosis to clinical trials of Porcupine inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2019-319126

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 73

Metadata

Authors
Kleeman, S. O., Koelzer, V. H., Jones, H. J., Vazquez, E. G., Davis, H., East, J. E., Arnold, R., Koppens, M. A., Blake, A., Domingo, E., Cunningham, C., Beggs, A. D., Pestinger, V., Loughrey, M. B., Wang, L.-M., Lannagan, T. R., Woods, S. L., Worthley, D., Tomlinson, I., Dunne, P. D., Maughan, T., & Leedham, S. J.
Venue
Gut
Publisher
BMJ
Published
2019-09-28
Volume
69
Issue
6
Pages
1092-1103
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2976026968
Cited by
73
References
5
FWCI
3.58
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification. https://app.cochat.ai/papers/10.1136/gutjnl-2019-319126
The paper
Kleeman, S. O., Koelzer, V. H., Jones, H. J., Vazquez, E. G., Davis, H., East, J. E., Arnold, R., Koppens, M. A., Blake, A., Domingo, E., Cunningham, C., Beggs, A. D., Pestinger, V., Loughrey, M. B., Wang, L.-M., Lannagan, T. R., Woods, S. L., Worthley, D., Tomlinson, I., . . . Leedham, S. J. (2020). Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification. Gut. https://doi.org/10.1136/gutjnl-2019-319126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.